Jeffrey Fischer

Echo Therapeutics: A Gross Disregard To Shareholder Value

Secondary equity offerings (& unfortunate shareholder dilution) are extremely common for development-stage medical companies, but the recent secondary offering by ECHO Therapeutics (NASDAQ:ECTE) demonstrates almost unparalleled disregard for shareholder value. Remaining shareholders should make note of the company's gross negligence exhibited in the management of its finances. Even if you believe strongly in Echo's Symphony glucose monitoring system, you may want to exit your position solely based on the lack of financial leadership that has led to a 50% decline in shareholder value from June 6 to June 14.

It has been a horrific comedy of errors at Echo, and it's difficult to pinpoint the most glaring blunder - that the company had already just tapped equity markets...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details